Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220063 | 0.84 | PDE2A (0.60) | PDE2AALDH1A1MAPTCES2MEN1 | |
| SCHEMBL16861424 | 0.82 | PDE2A (0.51) | PDE2AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3789260 | 0.81 | PDE2A (0.56) | PDE2AALDH1A1MAPTCES2MEN1 | |
| SCHEMBL21180446 | 0.80 | PDE2A (0.54) | PDE2ACES2MEN1TSHRKMT2A | |
| SCHEMBL22140214 | 0.78 | PDE2A (0.54) | PDE2AALDH1A1MAPTCES2 | |
| SCHEMBL11600693 | 0.78 | PDE2A (0.57) | PDE2AALDH1A1MAPTCES2MEN1 | |
| SCHEMBL11598716 | 0.78 | PDE2A (0.53) | PDE2AALDH1A1MAPTCES2MEN1 | |
| SCHEMBL11599763 | 0.78 | PDE2A (0.57) | PDE2AALDH1A1MAPTCES2MEN1 | |
| SCHEMBL963755 | 0.76 | PDE2A (0.58) | PDE2AALDH1A1CES2TSHRKIF11 | |
| SCHEMBL4792259 | 0.76 | PDE2A (0.51) | PDE2AALDH1A1CES2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PDE2A 1/4885ALDH1A1 608/4885MAPT 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.